Biotech and Pharmaceuticals
Novo Nordisk CEO says he’s confident about Wegovy supply, next-generation weight loss drugs
It’s been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo’s obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo’s stock has fallen more than 20% over the last year, […]
Read More
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Shares of Novo Nordisk rose on Wednesday after the company reported better-than-expected net profit in the fourth quarter amid soaring demand for its Wegovy obesity drugs, but forecast a slight slowdown in […]
Read More
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Happy Tuesday! Most people quit a highly popular class of weight loss and […]
Read More
Vaccine stocks fall as Senate panel advances RFK Jr.’s nomination for HHS secretary
FILE PHOTO: Robert F. Kennedy Jr., U.S. President Trump’s nominee to be secretary of Health and Human Services, testifies before a Senate Health, Education, Labor, and Pensions (HELP) Committee confirmation hearing on Capitol Hill in Washington, U.S., January 30, 2025. Nathan Howard | Reuters Shares of vaccine companies fell on Tuesday after a Senate panel […]
Read More
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company’s Covid products topped expectations and its broad cost-cutting efforts took […]
Read More
Merck’s 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Sopa Images | Lightrocket | Getty Images Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street’s expectations, as the company temporarily paused shipments of a key vaccine into China. The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 billion, lower than the $67.31 billion that analysts surveyed by […]
Read More
Trump tariffs could raise medication costs and exacerbate shortages, drug trade groups warn
Shana Novak | Stone | Getty Images President Donald Trump’s steep tariffs on Canada, Mexico and China could worsen existing drug shortages in the U.S., raise healthcare costs for patients and threaten cash-strapped generic drugmakers, some drug trade groups warn. Trump on Saturday announced he would impose a 25% tariff on nearly all goods shipped […]
Read More
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
An office building designed by Frank O. Gehry at the Novartis AG headquarters campus in Basel, Switzerland. Bloomberg | Getty Images Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose 16% on a constant currency basis […]
Read More
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters The Food and Drug Administration on Thursday approved Vertex Pharmaceuticals’ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. Vertex is now the first drugmaker in decades to gain U.S. […]
Read More
RFK Jr. stumbles over basics of Medicare, Medicaid during Senate confirmation hearings
Robert F. Kennedy Jr., U.S. President Trump’s nominee to be secretary of Health and Human Services, testifies before a Senate Health, Education, Labor, and Pensions (HELP) Committee confirmation hearing on Capitol Hill in Washington, U.S., Jan. 30, 2025. Nathan Howard | Reuters Robert F. Kennedy Jr., President Donald Trump’s pick to lead the Department of […]
Read More